[
  {
    "ts": "2025-11-28T08:09:21+00:00",
    "headline": "The Bull Case For Regeneron (REGN) Could Change Following European Approval of Dupixent for CSU Patients",
    "summary": "Regeneron Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent as a first-line treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12 and older who do not respond to antihistamines and are naive to anti-IgE therapy, based on positive Phase 3 clinical trial results. This marks the first innovation for CSU patients in Europe in over a decade and potentially opens access for approximately 270,000 eligible...",
    "url": "https://finance.yahoo.com/news/bull-case-regeneron-regn-could-080921441.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "50bd3c6e-bb21-322f-bfae-0efa35747f90",
      "content": {
        "id": "50bd3c6e-bb21-322f-bfae-0efa35747f90",
        "contentType": "STORY",
        "title": "The Bull Case For Regeneron (REGN) Could Change Following European Approval of Dupixent for CSU Patients",
        "description": "",
        "summary": "Regeneron Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent as a first-line treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12 and older who do not respond to antihistamines and are naive to anti-IgE therapy, based on positive Phase 3 clinical trial results. This marks the first innovation for CSU patients in Europe in over a decade and potentially opens access for approximately 270,000 eligible...",
        "pubDate": "2025-11-28T08:09:21Z",
        "displayTime": "2025-11-28T08:09:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w30LARiR1Z35GusfaFi.2g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3eDp_RSETU8kXm3usDK_gQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-regeneron-regn-could-080921441.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-regeneron-regn-could-080921441.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-28T07:19:50+00:00",
    "headline": "Deutsche Bank Maintains a Buy Rating on Sanofi (SNY)",
    "summary": "Sanofi (NASDAQ:SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi (NASDAQ:SNY) on November 25, setting a €110 price target. The same day, Sanofi (NASDAQ:SNY) announced the approval of Dupixent (dupilumab) by the European Commission for the treatment of “moderate-to-severe chronic […]",
    "url": "https://finance.yahoo.com/news/deutsche-bank-maintains-buy-rating-071950612.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "372377d2-dacc-34f6-b591-82764f977cbb",
      "content": {
        "id": "372377d2-dacc-34f6-b591-82764f977cbb",
        "contentType": "STORY",
        "title": "Deutsche Bank Maintains a Buy Rating on Sanofi (SNY)",
        "description": "",
        "summary": "Sanofi (NASDAQ:SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi (NASDAQ:SNY) on November 25, setting a €110 price target. The same day, Sanofi (NASDAQ:SNY) announced the approval of Dupixent (dupilumab) by the European Commission for the treatment of “moderate-to-severe chronic […]",
        "pubDate": "2025-11-28T07:19:50Z",
        "displayTime": "2025-11-28T07:19:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4f7369a8cd76489e18c06afee0976ddc",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OiLNv3YhiGdV9J6vk1l75Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4f7369a8cd76489e18c06afee0976ddc.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZlW0Wpx0Vz0_itMp4u_YGg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4f7369a8cd76489e18c06afee0976ddc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/deutsche-bank-maintains-buy-rating-071950612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/deutsche-bank-maintains-buy-rating-071950612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-28T12:11:26+00:00",
    "headline": "Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500?",
    "summary": "Regeneron Pharmaceuticals has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.",
    "url": "https://www.barchart.com/story/news/36355953/is-regeneron-pharmaceuticals-stock-underperforming-the-s-p-500",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "e3c3ac9b-e32c-39fa-b947-561fb946e6cc",
      "content": {
        "id": "e3c3ac9b-e32c-39fa-b947-561fb946e6cc",
        "contentType": "STORY",
        "title": "Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500?",
        "description": "",
        "summary": "Regeneron Pharmaceuticals has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.",
        "pubDate": "2025-11-28T12:11:26Z",
        "displayTime": "2025-11-28T12:11:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/b5fca612b3a61a67a2a2b488a7827af2",
          "originalWidth": 1000,
          "originalHeight": 750,
          "caption": "Regeneron Pharmaceuticals, Inc_ logo on phone-by Piotr Swat via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/13cIDE5L8IVJcjoF_eSu9Q--~B/aD03NTA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/b5fca612b3a61a67a2a2b488a7827af2.cf.webp",
              "width": 1000,
              "height": 750,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eAqOvAl854RedqYxYy.YBw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/b5fca612b3a61a67a2a2b488a7827af2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36355953/is-regeneron-pharmaceuticals-stock-underperforming-the-s-p-500",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-stock-underperforming-p-121126888.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-28T14:59:00+00:00",
    "headline": "Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?",
    "summary": "Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.",
    "url": "https://finance.yahoo.com/news/ntlas-vivo-pipeline-drive-long-145900819.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "4f071f11-df90-3f6e-a4b7-80c32dcb6399",
      "content": {
        "id": "4f071f11-df90-3f6e-a4b7-80c32dcb6399",
        "contentType": "STORY",
        "title": "Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?",
        "description": "",
        "summary": "Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.",
        "pubDate": "2025-11-28T14:59:00Z",
        "displayTime": "2025-11-28T14:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhUbp770QgvNMyXdM9XKnA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ii2rwaxi8Dao2zrk4I.W2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ntlas-vivo-pipeline-drive-long-145900819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ntlas-vivo-pipeline-drive-long-145900819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": null,
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]